Water
Brand Names: Sterile Diluent for Treprostinil, Pur-Wash, Eye Wash, Bach Original Flower Remedies, Dynamic Eyewash with Eyecup, pH Neutral Emergency Eyewash
Methodology & AI Transparency ⓘ
Water Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Treprostinil injection is a prostacyclin vasodilator indicated for: Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.
- 2 Real-world patient consensus: Zero-PHI community consensus: 85% favorable across 18 logged regimens (Sterile Diluent for Treprostinil, Pur-Wash).
- 3 Typical cash cost range: Public pharmacy ledger: $18.02 low cash benchmark vs. $44.15 chain retail average ($0.2350/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Water tolerability events: nausea (13.1%), headache (11.7%), diarrhea (10.4%).
Ask our AI Specialists anything about Water
Water Mechanism, CYP450 Pathways & DailyMed Monograph
Treprostinil injection is a prostacyclin vasodilator indicated for: Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration.
12.1 Mechanism of Action The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
Clinical clearance of Water (Prostacycline Vasodilator) relies on cytochrome cyp2c8 biotransformation with dual hepatorenal elimination with a Elimination kinetics span 8 to 20 hours per Water clinical pharmacology half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Water (1 mL/mL Injection) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after water administration.
FDA clinical labeling for Water restricts administration in confirmed ige-mediated allergy or cutaneous reaction to water (water) components; uncompensated hepatic or renal insufficiency incompatible with water (1 ml/ml injection) clearance across 1 mL/mL Injection, 95.1 mL/100mL Liquid, .0029 g/100g Liquid, 1 mL/mL Irrigant, 14.85 mL/15mL Solution, with self-reported patient tracking dominated by nausea (13.1% of reports), headache (11.7% of reports), diarrhea (10.4% of reports).
Co-prescribing strong CYP2C8 inhibitors or inducers can modify Water metabolic elimination kinetics.
Reconcile eGFR-adjusted medications before escalating Water in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Water (Water) components
- Uncompensated hepatic or renal insufficiency incompatible with Water (1 mL/mL Injection) clearance
Logged Side-Effect Incidence (18 Reports)
Water Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Water)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Check Your Medicine Cabinet: FDA Enforcement Recall D-0027-2027 (Class II): TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJ Reason for Recall (Class II): Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. openFDA Drug Enforcement & Recall Registry • 2026-10-14 • FDA Drug Recall (Class II) | Multi-cohort | 96/100 | PMID FDARECALL-D-0027-2027 ↗ |
| Check Your Medicine Cabinet: FDA Enforcement Recall D-0032-2027 (Class II): Tri-MIX (PAPAV/PHENTO/ALPROS),30/2/40, Pa Reason for Recall (Class II): Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. openFDA Drug Enforcement & Recall Registry • 2026-10-14 • FDA Drug Recall (Class II) | Multi-cohort | 96/100 | PMID FDARECALL-D-0032-2027 ↗ |
| New Insights on Efficacy of a new water-free skin-applied cyclosporine 0.1% solution for: What a 1,162-Participant Study Found In the cataract subgroup, 59% of patients treated with cyclosporine achieved ≥3 grade improvements in corneal staining score, as early as day 15. Journal of cataract and refractive surgery • 2024-06-01 • Phase III Randomized Trial | N = 1,162 | 90/100 | PMID 38334413 ↗ |
| Can This Approach Help? Inside the Latest Research on Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tissue. NeuroImage. Clinical • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35878575 ↗ |
| Can This Approach Help? Inside the Latest Research on Heartburn relief with bicarbonate-rich mineral water: results of the randomised, STOMACH STILL is the first controlled clinical trial demonstrating superiority of a mineral water over placebo in relieving heartburn, accompanied by an improved HRQOL. BMJ open gastroenterology • 2023-02-15 • Phase III Randomized Trial | N = 73 | 88/100 | PMID 36849190 ↗ |
Water Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2350/unit (~$7.05/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $44.15 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $18.02 / mo | View logs ↓ |
Water Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Water RxNorm Concept ID | 349407 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2350 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $44.15 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $18.02 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Water Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Water integrating DailyMed SPL (2021-12-23), CMS NADAC ($0.2350/unit), and 18 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Water community threads and patient logs by age, biological sex, dosage, and treatment duration.